Clinical Characteristics
| Characteristic | Data |
|---|---|
| Median age (y) | 71 (range, 43–85) |
| Median pre-CTX PSA level (ng/mL) | |
| mHSPC | 15 (IQR, 2–39) |
| mCRPC | 45 (IQR, 10–155) |
| Gleason score (n) | |
| ≤7 | 31 (30%) |
| ≥8 | 67 (65%) |
| NA | 5 (5%) |
| ECOG performance status (n) | |
| 0 | 53 (52%) |
| 1 | 26 (25%) |
| 2 | 1 (1%) |
| NA | 23 (22%) |
| Castration status (n) | |
| mHSPC | 57 (55%) |
| mCRPC | 46 (45%) |
| Pre-CTX miTNM staging (n) | |
| No distant metastasis (M0) | 6 (6%) |
| Extrapelvic node metastasis (M1a) | 72 (70%) |
| Bone metastasis (M1b) | 80 (78%) |
| Visceral metastasis (M1c) | 16 (16%) |
| Pattern of metastatic spread (n) | |
| LN only | 21 (21%) |
| Bone only | 9 (9%) |
| Visceral only | 1 (1%) |
| LN and bone | 54 (52%) |
| LN and visceral organs | 1 (1%) |
| LN, bone, and visceral organs | 14 (14%) |
| LN, bone, and others (subcutaneous, skin metastasis) | 2 (2%) |
| Bone and others (penis) | 1 (1%) |
| Local treatment for PC (n) | |
| Prostatectomy ± lymphadenectomy | 58 (56%) |
| Primary EBRT | 13 (13%) |
| Type of chemotherapy (n) | |
| Docetaxel | 95 (92%) |
| Cabazitaxel | 7 (7%) |
| Docetaxel and cabazitaxel | 1 (1%) |
| Reduction in serum PSA ≥ 50% (n) | 61 (59%) |
CTX = chemotherapy; ECOG = Eastern Cooperative Oncology Group; EBRT = external beam radiotherapy; NA = not available; LN = lymph nodes.